Dendreon shares jump on news of prostate drug’s European launch

(Reuters) – Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

    

Leave a Reply

Your email address will not be published.